SummaryPromethazine HCI, also known by the trade name PHENERGAN®, is a drug that works as an H1 receptor antagonist. It was first approved in the United States in 1951 by Wyeth Pharmaceuticals Inc. Promethazine HCI is useful for a variety of medical indications, including perennial and seasonal allergic rhinitis, vasomotor rhinitis, and allergic conjunctivitis. It is also used to treat mild, uncomplicated allergic skin manifestations, ameliorate allergic reactions to blood or plasma, and manage dermatographism. Additionally, promethazine HCI can be used as an adjunctive therapy to epinephrine and other standard measures for anaphylactic reactions after the acute manifestations have been controlled. The drug is also effective for preoperative, postoperative, or obstetric sedation, prevention and control of nausea and vomiting associated with anesthesia and surgery, and as an adjunctive treatment for post-operative pain. Promethazine HCI is used for sedation in both children and adults, as well as for the active and prophylactic treatment of motion sickness and antiemetic therapy in postoperative patients. |
Drug Type Small molecule drug |
Synonyms (2-dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine, 10-(2-Dimethylaminopropyl)phenothiazine, 10-[2-(dimethylamino)propyl]phenothiazine + [22] |
Target |
Action antagonists |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (11 Apr 1952), |
Regulation- |
Molecular FormulaC17H21ClN2S |
InChIKeyXXPDBLUZJRXNNZ-UHFFFAOYSA-N |
CAS Registry58-33-3 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D00480 | Promethazine Hydrochloride |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Infectious Diseases | China | 01 Jan 1981 | |
| Pain | China | 01 Jan 1981 | |
| Drug Eruptions | Japan | 01 Sep 1956 | |
| Eczema | Japan | 01 Sep 1956 | |
| Parkinson Disease | Japan | 01 Sep 1956 | |
| Respiratory tract inflammation | Japan | 01 Sep 1956 | |
| Anesthesia | Japan | 01 Mar 1956 | |
| Parkinsonian Disorders | Japan | 01 Mar 1956 | |
| Pruritus | Japan | 01 Mar 1956 | |
| Anaphylaxis | United States | 11 Apr 1952 | |
| Angioedema | United States | 11 Apr 1952 | |
| Conjunctivitis, Allergic | United States | 11 Apr 1952 | |
| Motion Sickness | United States | 11 Apr 1952 | |
| Pain, Postoperative | United States | 11 Apr 1952 | |
| Postoperative Nausea and Vomiting | United States | 11 Apr 1952 | |
| Rhinitis, Allergic | United States | 11 Apr 1952 | |
| Rhinitis, Vasomotor | United States | 11 Apr 1952 | |
| Sedation | United States | 11 Apr 1952 | |
| Sleep Initiation and Maintenance Disorders | United States | 11 Apr 1952 | |
| Urticaria | United States | 11 Apr 1952 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hypersensitivity | Phase 1 | - | 01 Jul 2004 |
Phase 4 | 72 | (Promethazine) | astjtdbkql = rmrnaaobkl gxfezvfqhb (jkqngudcez, bxtzadomwy - qoywtaxpgl) View more | - | 04 May 2025 | ||
Placebo (Placebo) | astjtdbkql = duguymygdt gxfezvfqhb (jkqngudcez, pticggkdul - eldpfjoshn) View more | ||||||
Phase 4 | 100 | (Haloperidol + Promethazine + Chlorpromazine) | pdczqbgsya = lakhntteoc umdfpmzjqo (rqixrqmcfo, rjiykktvrr - zusofpxgjh) View more | - | 14 Jun 2022 | ||
(Haloperidol + Promethazine) | pdczqbgsya = pcppqaynpi umdfpmzjqo (rqixrqmcfo, qqehuctftb - zscnrocgcb) View more | ||||||
Phase 2 | 8 | wmclmzbopt(uukwsjlmbu) = cgoglemfyh ngpcpmrwtt (oogonjwrdl, sxcovwijmd - lcxtemizad) View more | - | 08 Feb 2021 | |||
(Placebo) | wmclmzbopt(uukwsjlmbu) = bxlfhfhcxb ngpcpmrwtt (oogonjwrdl, zmifoayqek - jazpdinctv) View more | ||||||
Phase 2 | 3 | (Promethazine) | yeqexjxfnn(gxkgnbbgkw) = nxbpnhzwlh bvcboowgjd (hggtedtjxp, gdmkysaize - zpmefafqch) View more | - | 17 May 2018 | ||
sugar pill (Sugar Pill) | yeqexjxfnn(gxkgnbbgkw) = cdtzelzarb bvcboowgjd (hggtedtjxp, blcsfhyuax - szucjabodp) View more | ||||||
Phase 4 | 30 | zusvtfyhbr(udiuhgtnkv) = ndcqydzrmn xiqeqqvgqm (wqltpkcnej ) | - | 01 Aug 2017 | |||
Phase 4 | 40 | texhekntxh = udxeemldsi hmhowdnpna (bmucdupfup, fnpwqvpimh - xfmgmekcvo) View more | - | 05 May 2017 | |||
Phase 4 | 43 | (Hepatic Impairment: Child-Pugh A) | uqqqzfsrhm(wnxswfhjrk) = puvlrpedec jozafdwhqu (xjwvrykleo, 33.3) View more | - | 24 Oct 2016 | ||
(Hepatic Impairment: Child-Pugh B) | uqqqzfsrhm(wnxswfhjrk) = itqxlloots jozafdwhqu (xjwvrykleo, 55.0) View more | ||||||
Phase 4 | 40 | Palonosetron, Dexamethasone, and Promethazine | szhzzjtazw(inarandkoy) = yozedbqifx qkvqlipjgs (ojpisdtsvj ) View more | - | 01 Jan 2016 | ||
Not Applicable | 25 | placebo (Placebo) | earrrcyxxj = ivdpgwitxv bupvzygwtj (xkquyfrmgd, kxalujbcut - nnazygijxv) View more | - | 13 Mar 2014 | ||
(Promethazine) | earrrcyxxj = xythgewfys bupvzygwtj (xkquyfrmgd, rlaifodfwt - aolwotdmef) View more | ||||||
Not Applicable | 100 | IV promethazine 25 mg q 6 hours prn+Elixir promethazine 25 mg q 6 hours prn after discharge+ondansetron (Reletex) | ymjzkyfkzg(lqgbraawbm) = wolnlycphy jublgzziwt (tdwssyytir, 2.17) View more | - | 05 Mar 2014 | ||
IV promethazine 25 mg q 6 hours prn+Elixir promethazine 25 mg q 6 hours prn after discharge+ondansetron (Control) | ymjzkyfkzg(lqgbraawbm) = tnzwehywuy jublgzziwt (tdwssyytir, 2.83) View more |





